SCHEMBL23501019

SCHEMBL23501019

CCOC(=O)c1coc(NC2Cc3ccccc3C2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.51
CCNT1 O60563 1/20 0.44
CYP1A2 P05177 1/20 0.43
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40
GABRA4 P48169 1/20 0.40
GABRE P78334 1/20 0.40
GABRA6 Q16445 1/20 0.40
GABRG1 Q8N1C3 1/20 0.40
GABRG3 Q99928 1/20 0.40
GABRQ Q9UN88 1/20 0.40
MAPT P10636 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29878527 1.00 NLRP3 (0.51) NLRP3CCNT1CYP1A2GABRPGABRD
SCHEMBL29878350 0.83 MAPK1 (0.38) NLRP3CCNT1MAPK1HRH3NPC1
SCHEMBL23519688 0.83 MAPK1 (0.38) NLRP3CCNT1MAPK1HRH3NPC1
SCHEMBL23500746 0.81 GBA1 (0.39) MAPTNPC1RAB9AMTNR1AMTNR1B
SCHEMBL29878512 0.81 GBA1 (0.39) MAPTNPC1RAB9AMTNR1AMTNR1B
SCHEMBL29879154 0.80 NLRP3 (0.34) NLRP3CCNT1HRH3NPC1RAB9A
SCHEMBL14309732 0.78 NLRP3 (0.47) NLRP3CCNT1CYP1A2MAPTTTK
SCHEMBL553902 0.76 NLRP3 (0.56) NLRP3CYP1A2GABRA2GABRB2MAPT
SCHEMBL25124225 0.76 ENPP2 (0.49) CYP1A2GABRPGABRDGABRA1GABRB1
SCHEMBL23500717 0.74 SMN1; SMN2 (0.52) KMT2AATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230069174-A1 NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-03-02 US disclosed
CN-114901658-A Nitrogen-containing heterocyclic ring autotaxin inhibitor, and composition and application thereof 四川海思科制药有限公司 2022-08-12 CN disclosed
WO-2021115375-A1 NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF 四川海思科制药有限公司 2021-06-17 WO disclosed
WO-2021115375-A1 NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF 四川海思科制药有限公司 2021-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230069174-A1 NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF ENPP2, NMT2, NMT1 NLRP3 395/4885CCNT1 1618/4885CYP1A2 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.